Global Grass Pollen Allergy Drug Market Overview:
Pollen allergy is an allergic condition affecting the mucous membranes of the nose and the eyes etc., usually characterized by nasal discharge, nasal congestion, and itchy and watery eyes, itchy nose, inner ears and roof of the mouth, that are caused by a hypersensitivity to airborne pollen, such as the pollen of trees, grasses, and weeds. Grass pollen allergy drugs can help ease symptoms of pollen allergy. Based on the drug type, the market has been segmented into BM-32, Pollinex Quattro Grass, and Others.
- Exponential Rise in Number of Patient Suffering From Pollen Based Allergies and More Precisely Hay Fever
- Weather Variables, Mainly Air Temperature, Sunlight, and Rainfall Together With Carbon Dioxide (CO2)
- The Growing Number of Pollen Allergies among the Children’s
- Lack of Permanent Cure to Grass Pollen Allergy Disease and Home Based Diagnosis
- The Increasing Grass Pollen Allergy Incidences among the North America & Oceana Regions
Some of the key players profiled in the report are Allergy Therapeutics plc. (United Kingdom), Allergopharma Joachim Ganzer KG (Germany), Circassia Pharmaceuticals Plc (United Kingdom), Laboratorios LETI S.L. (Spain), Anergis SA (Switzerland), Biomay AG (Austria), ALK-Abello A/S (Denmark), HAL Allergy BV (Netherlands) and Roxall Medizin GmbH (Germany). Analyst at AdvanceMarketAnalytics see United Kingdom, German Players to retain maximum share of Global Grass Pollen Allergy Drug market by 2024.
On 25 April 2019, Allergy Therapeutics (United Kingdom) got the regulatory green light for phase III grass pollen trial. The company has confirmed phase III trials of its short-course inoculation for grass pollen-induced hay fever will get underway in the second half of 2020.
On 22 Aug 2018, ALK has announced that the European regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities via the decentralized procedure, with Germany as the reference member state.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Grass Pollen Allergy Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Grass Pollen Allergy Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Grass Pollen Allergy Drug Manufacturers, Grass Pollen Allergy Drug Raw Material Suppliers, Grass Pollen Allergy Drug Traders/Distributors, Grass Pollen Allergy Importer/Exporter, Research Institutes, Regulatory & Government Bodies, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.